NCT01501942 - Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2013

Conditions

Asthma

Interventions

DRUG

AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide

AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.

DRUG

Buffered Saline

The matching placebo is an oral solution of phosphate buffered saline

Trial Locations (2)

L8N 3Z5

McMaster University, Hamilton

G1V 4G5

Institut de cardiologie et de pneumologie de l'Hôpital Laval, Laval